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Disease Mongering in Neurological Disorders 
 




“Diseases mongering”, than a simple definition would be enforced "to promote or sell 
disease". The main and common characteristhics of all these "diseases" is that they are 
amenable to treatment with drugs. So, the pharmaceutical industry redefining the concept 
of disease, the normal and pathological. In Neurology exploits the deepest atavistic fears 
of suffering and death. We select some diseases, the choise was based on lack or weak 
evidence in definition of disease; or cost benefit of treatment; or the new clasiffication 
that assign criteria of severity of one disease. In everything this situation implied use of 
expensive treatments. The entities included, Attention deficit hyperactivity disorder, in 
adults, Multiple Sclerosis, Mild Cognitive Impairment, Drug Resistant Epilepsy, 
Amyotrophic lateral sclerosis, Excessive daytime sleepiness/ Chronic Fatigue. In 
developing countries the impact of this situation is even worse for the scarce resources 
and inequitable health condition. Health professionals become aware of this situation. 
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1  Introduction  
If out of curiosity, the readers take a few seconds to search on the Internet the expression 
“diseases mongering”, they will see that "to promote or sell disease" is an enforced 
definition. They will also find out that the term competes in popularity with many 
frequently used words, even with popular actors or sportsmen. Besides it will appear a 
number of “new diseases" or novel groupings or categories of “old diseases”. The main 
and common characteristic of all these "diseases" is that they are amenable to be treated 
with drugs. The first reason seems to be the advances in scientific knowledge. However, 
we should incorporate other considerations such as the interest of the pharmaceutical 
industry in selling their products.  
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2  Preliminary Notes 
Almost 20 years ago, Lynn Payer [1] used the term “disease mongering” for the first time 
as the strategy of the pharmaceutical industry to expand the boundaries of treatable illness 
in order to increase the market (Table 1) [2]. This concept was recently defined as “the 
selling of sickness that widens the boundaries of illness and grows the markets for those 
who sell and deliver treatments.” [3] 
Therefore, the pharmaceutical industry redefines what is normal and what is pathological 
modifying the concept of disease. Much disease mongering relies on considering normal 
biological or social variation as pathologies. It also is based on the portrayal of disease 
risk factors as if it was a pathological state in itself. The vicious circle is completed when 
pharmaceuticals are used to treat risk factors because “anyone who takes medicines is by 
definition a patient” [4, 5, 6].  
Disease mongering exploits the deepest atavistic fears of suffering and death. In 
neurology added aspects are related to cognitive function, or illness that cause great 
disability, high mortality, or are surrounded by stigma.  
The principal aim of this paper is generate awareness in neurologists about of relatively 
new situation. We selected some “new diseases” or disease mongering aspects in “old 
disease” (Table 2). Although this corpus is just a sample, it is useful to remark the effect 
of disease mongering in neurology field. The choice was based on lack or weak evidence 
in one or more condition: a- definition of disease; or b- cost benefit analysis of drug 
treatment; or c- the use of new classification that assign criteria of severity in a disease. In 
every case, this situation implies the use of expensive treatments. We describe a brief 
review of each of the entities included. 
There is an important advertising campaign aimed at potential consumers in order to 
“improve cognitive functions” in mentally and neurologically healthy people, this 
statement is very complexe and ambiguous. However, there is a very large offer of drugs. 
The prescription of modafinil, adrafinil, methylphenidate, inderal, piracetam, aniracetam, 
amphetamines has increased in the last time [7]. 
 
 
3  Main Results  
ATTENTION DEFICIT HYPERACTIVITY DISORDER IN ADULTS PATIENTS (ADHD)  
National Institute for Health and Clinical Excellence (NICE, 2011) highlights the weak 
evidence in the definition of this "disease": “this would be best conducted as an 
epidemiological survey to answer the ADHD in adults”. In 1986, Nasrallah et al. [8] 
reported brain atrophy in adult males treated with amphetamines during childhood 
concluding: “since all of the HK/MBD [hyperkinetic/ minimal brain dysfunction] patients 
had been treated with psychostimulants, cortical atrophy may be a long-term adverse 
effect of this treatment”. In spite of this research other authors published “Recent 
investigations with magnetic resonance imaging (MRI) provide converging evidence that 
a refined phenotype of ADHD is characterized by reduced size of the frontal lobes and 
basal ganglia “ [9]. However there had been no such studies of ADHD-untreated cohorts 
[10].  
Although ADHD is a recognized pathology (ICD, DSM-IV) in children, we cannot stop 
thinking that the possibility of a drug treatment can shoot some diagnostics, which does 
not happen with disorders no treatable with drugs such as dyslexia. ADHD is a symptom, 
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a syndrome or a disease diagnosed in 7.8% of U.S. children between 4-17 years (4.4 
million children), according to results of a parent survey conducted in 2003, of which 
56% were medicated at the time. Also in Spain the consumption of methylphenidate 
fivefold from 1992 to 2001 with an estimated increase in annual consumption of 8%. 
Could be possible to reduce diagnoses understanding ADHD from a model of mental 
functioning rather than from a model based on observable behavior and the sum of 
symptoms, sometimes collected through global questionnaires [5, 11]. In recent studies, in 
children and in adults, observed increased in the prevalence of this diagnosis with a trend 
of increasing prescribing of ADHD drug treatment, however no demonstrate more 
evidence diagnostic [12, 13, 14] 
 
EXCESSIVE DAYTIME SLEEPINESS (EDS) AND CHRONIC FATIGUE 
Both categories EDS and Chronic Fatigue, can be considered together taking into account 
that there is overlaping on the definition used to define each of them, even their existence as 
diseases or syndromes is contested [15]. Nevertheless, there is abundant mass media 
advertising refered to the “good results” achieved with psychostimulants. A recently 
editorial of Neurology [16], describe in relation a paper published in the same journal [17], 
as despite having a Class I level of evidence in the treatment protocol with modafinil in 
EDS and chronic fatigue, detailed analysis showed did not improve fatigue symptoms, nor 
were there any benefits in the psychomotor vigilance test [18].  
 
MILD COGNITIVE IMPAIRMENT (MCI) 
Despite there are clinical guides that contemplate mild cognitive impairment as a defined 
disease [19], their consideration as a clinical entity according to some authors is still a 
matter of debate. In this context of uncertainty, clinical trials have been developed in the 
attempt to study the effects of ChEIs (donepezil, rivastigmine, and galantamine) in 
delaying the conversion from MCI to Alzheimer disease or dementia [20]. Although the 
use of ChEIs in MCI was not associated thus far, with any delay in the onset of AD or 
dementia, the safety profile showed that the risks associated with ChEIs were not 
negligible [21]. However appears information in scientific journals and in mass media 
that encourages the use of these drugs to "prevent" these dreaded diseases. 
The disorders that mainly leads to a deterioration of motor skill as multiple sclerosis or 
fatal disorder such as amyotrophic lateral sclerosis, high influence for patients, healthcare 
systems, and society as a whole:  
 
MULTIPLE SCLEROSIS  
It is remarkable the profound analysis made by James Raftery [22]. What happened with 
multiple sclerosis risk sharing scheme in United Kingdom represent a unique situation 
where the NHS is paying for thousands of patients to receive drugs that monitoring data 
suggest are not effective. This scheme was set up in 2002 after the National Institute for 
Health and Clinical Excellence (NICE) recommended against the use of interferon beta 
and glatiramer acetate. It is based on outcome analysis, not only in cost benefit analysis. 
There was an agreement that prices would be reduced if patient outcomes were worse 
than predicted. Disease progression was not only worse than predicted by the model used 
by NICE [23], but even worse than the untreated control group. In the same way, 
Cochrane multiple sclerosis group has proposed that the efficacy of interferon on 
exacerbations and disease progression in patients with relapsing remitting MS was modest 
after one and two years of treatment. Interferon administered by the oral route was not 
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effective for prevention of relapses. Longer follow-up and more uniform reporting of 
clinical and MRI outcomes among these trials might have allowed for a more convincing 
conclusion [24, 25]. Recently in a systematic review indicating that the anti-inflammatory 
effect of Interferon β is unable to prevent MS progression once it has become established 
[26]. Nevertheless, there was not any price reduction, moreover, in our country the prices 
are more than double that in developed countries [27].  
  
AMYOTROPHIC LATERAL SCLEROSIS (ALS)  
Several ALS therapies have shown promising results in preclinical models of motor 
neuron disease. However, most of them failed in human studies. A remarkable progress in 
understanding the cellular mechanisms of motor neuron degeneration has not been 
matched with the development of therapeutic strategies to prevent disease progression or 
to extend survival longer clinical trials [28]. 
The current estimations of the cost-effectiveness of riluzole must be analized cautiously. 
The uncertainty of the benefits in the economic analysis is due to the overconsideration of 
the survival gain that is experienced in a determined disease stage. The quality of life 
utility weights upon ALS health states and the gained life expectancy for individuals who 
take riluzole. Estimates from different trials suggest a gain in median tracheostomy free 
survival time of 2 months to 4 months [29, 30, 31]. This treatment implies an increase in 
costs for the health service. In addition to the unsatisfactory results, the great impact of 
these costs in developing countries is almost impossible to afford.  
 
DRUG RESISTANT EPILEPSY 
Epilepsy is one of the most prevalent neurological disorders that can be effectively 
prevented and treated at an affordable cost for most of patients. Different epidemiological 
studies estimated that up to 22.5% of patients with epilepsy have drug-resistant epilepsy. 
In this group the use of new drugs, more expensive, or nondrug therapy such as epilepsy 
surgery should be considered [32]. 
A new definition recently proposed for ILAE (International League against Epilepsy) [33] 
includes in this category patients that present seizures, opposed to patient seizure- free, 
without special consideration, i.e. seizures without consciousness, or only during sleep, or 
one seizure by year. Although before to mentioned definition, there was no unified 
definition of drug resistant epilepsy, those patients who had affected their quality of life 
were included as drug resistant or refractory epilepsy. Numerous of patients now included 
in this group, were not consider in this category previous to recent definition [34]. It is 
evident that in this new classification the concept quality adjusted life year (cost/QALY) 
is not considered, and allows that many more patients are liable to receive more expensive 
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4  Labels of Figures and Tables 
Table 1: Mogering Disease Definition 
Taking a normal function and implying that there is something wrong with it and should 
be treated 
To attribute the suffering of a disease where there is not necessarily an actual illness 
Increase the ranges of diseases prevalence 
Define a health condition as "absence of disease" 
Select the use of statistics to exaggerate the benefits of treatment 
Take a common symptom that can mean anything and make it sound like a symptom of a 
serious illness 
Promote anxiety or fear that healthy people get sick in the future 
Promote aggressive treatment with pharmaceuticals for minor illnesses or symptoms 
Entering new questionable diagnoses, that are difficult to distinguish from normal life 
Promotion of pharmaceuticals as first-line solutions for problems not previously 
considered as medical problems 
From Payer, Lynn  
 
Table 2: Disease Mongering In Neurology 
“DISEASE” CONDITION 
Attention deficit hyperactivity disorder in adults patients 
(ADHD) 
Definition of disease 
Multiple Sclerosis Cost benefit analysis of drug 
treatment 
Excessive daytime sleepiness (EDS) / Chronic Fatigue Definition of disease 
Drug Resistant Epilepsy  New criteria of clasiffication 
Amyotrophic lateral sclerosis (ALS) Cost benefit analysis of drug 
treatment 
Mild Cognitive Impairment (MCI) Definition of disease 
 
 
5  Conclusion 
Pharmaceutical companies are not the only actors in this field. Physicians, patients, mass 
media, politicians, also play a role with different contributions, but together multiply the 
effect of disease mongering. There must be awareness of all stakeholders to know this 
problem at the moment of making decisions related with diagnosis and prescription. 
It is necessary the implementation issues in latinoamerica as the “Sunshine Act”, part of 
the Affordable Care Act, created in USA, requires manufacturers to submit a list of 
physicians and teaching hospitals who received from them a transfer of value, but neither 
was implemented even in the country of origin. 
We consider it is essential that health professionals become aware of this relatively new 
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condition, which increases more and more, probably have even more serious impact on 
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